<p>The financial markets this week are proving that not all the action is confined to the mega-cap tech giants. I'm told that institutional money is quietly rotating into a diverse basket of mid-cap and cross-sector equities, navigating a complex web of recent developments. From steep sell-offs in semiconductor manufacturing infrastructure to under-the-radar defense contracts and massive biotech capital raises, a significant overhaul is underway among these peripheral players. Here is the latest on the companies navigating these 2026 market currents.</p>

<h3>Onto Innovation (ONTO.US)</h3>
<p>It has been a rough stretch recently for semiconductor equipment manufacturers, and Onto Innovation is feeling the heat. According to people familiar with the matter, the broader sector sell-off dragged the company's shares down by over 10% earlier this month. But beneath the surface, the company is targeting future capacity. Earlier in 2026, Onto successfully qualified its Dragonfly G5 system for 2.5D AI packaging applications and quickly locked in a strategic partnership with Rigaku to advance next-generation process control. While near-term sentiment remains cautious, executives are betting that these AI-driven packaging solutions will serve as a crucial revenue catalyst later this year.</p>

<h3>Hitachi (HTHIY.US)</h3>
<p>The Japanese conglomerate is executing one of its most aggressive AI pushes in recent memory. I'm told that Hitachi is not just making incremental updates; it is diving headfirst into physical AI through newly cemented strategic alliances with both Anthropic and Google Cloud. Furthermore, its US subsidiary GlobalLogic is in the process of acquiring the German data firm synvert. During its June 2026 investor day, management sent a clear signal that the integration of green energy mobility and digital systems is accelerating rapidly, reshaping its long-term narrative for stateside ADR investors.</p>

<h3>Kopin (KOPN.US)</h3>
<p>Kopin is officially translating its optical tech into military hardware. The company recently secured multiple prototype orders for its Sentinel FPV headsets, marking its formal entry into the US government's drone superiority initiatives. The initial USD 3.2 million order is just the beginning—if successful, this pipeline could result in the delivery of up to 40,000 goggles by late 2028. For a company that posted roughly USD 10 million in total preliminary revenue for the first quarter of 2026, shifting focus toward non-product revenue and defense contracts is a critical strategy. They also just opened a new optical design center in Dallas to support this exact expansion.</p>

<h3>Taysha Gene Therapies (TSHA.US)</h3>
<p>The biotech financing window remains wide open for the right candidates. Taysha Gene Therapies capitalized on this by launching a massive USD 200 million underwritten public offering in late June 2026. This came immediately on the heels of positive longer-term clinical data from its REVEAL Phase 1/2 trial for Rett syndrome. Wall Street analysts reacted swiftly, with firms aggressively raising their price targets. I understand that this fresh injection of capital will provide the necessary runway to advance its core AAV-based gene therapy programs through the next critical regulatory phases.</p>

<h3>Also</h3>
<ul>
<li><strong>Verastem (VSTM.US)</strong>: The oncology firm delivered better-than-expected EPS results in Q1 2026. I'm told management is moving quickly to update its RAS/MAPK pipeline strategy following promising clinical activity for its advanced solid tumor treatments.</li>
<li><strong>Alpha Tau Medical (DRTSW.US)</strong>: After securing Japanese approval for head and neck cancer earlier in 2026, the clinical-stage oncology company just received the green light from the FDA for its REGAIN trial in recurrent glioblastoma, boosting confidence in its proprietary Alpha DaRT technology.</li>
<li><strong>TrueBlue (TBI.US)</strong>: The workforce solutions provider has officially put its proxy battle with EHS Investments in the rearview mirror. With a newly agreed-upon board member, the company is now refocusing on its core flexible staffing operations amid a shifting labor market.</li>
<li><strong>Ping An Insurance (PNGAY.US)</strong>: The insurance giant is aggressively expanding its healthcare ecosystem in 2026, recently rolling out its AI doctor services to tens of millions of active users. Crucially, the company firmly shut down rumors that it would take over distressed property developers, easing the nerves of foreign investors.</li>
<li><strong>China Mengniu Dairy (CIADY.US)</strong>: As a bellwether for Chinese consumer staples, Mengniu's ADR performance continues to reflect the broader macroeconomic sentiment as domestic dairy consumption enters a more mature, highly competitive phase in 2026.</li>
<li><strong>ProShares Trust II VIX Mid-Term Futures (VIXM.US)</strong>: With recent market jitters and volatility creeping back into mega-cap tech stocks, institutional money continues to utilize this fund as an essential hedging instrument against mid-term downside risks.</li>
</ul>

<p><em>This article does not constitute investment advice.</em></p>

VSTM

HTHIY

KOPN

DRTSW

TSHA

PNGAY

CIADY

ONTO

<p>This week's market action extends far beyond the typical Silicon Valley heavyweights. From a significant semiconductor equipment sell-off to pivotal medical breakthroughs and major defense drone contracts, mid-cap and peripheral stocks are experiencing sweeping overhauls.</p>

Under the Radar: The Tech, Biotech, and Defense Shifts You Missed